Hemosol (Toronto) said that pursuant to Nasdaq Marketplace Rule 4350(b)(1)(B), which requires an issuer that receives an audit opinion that contains a going concern qualification to make a public announcement disclosing the receipt of such qualification, Hemosol reported that the auditors’ report on Hemosol’s financial statements for the year ended Dec. 31, 2004, contained in Hemosol’s an-nual report on Form 20-F, filed with the Securities and Exchange Commission on June 30, contained a “going concern” qualification.
Hemosol is a biopharmaceutical company focused on the development and manufacturing of biologics, particularly blood-related proteins.
Health Dialog Data Service changes name
Health Dialog Services (Boston) has changed the name of its analytics subsidiary from Health Dialog Data Service (HDDS) to Health Dialog Analytic Solutions (HDAS). The new name reflects the "scope and sophistication" of Health Dialog's analytic offerings, said David Wennberg, president and CEO of HDAS.
HDAS is grounded in more than 30 years of academic research by Drs. John and David Wennberg on unwarranted variation in healthcare. The research focuses on the overuse, underuse and misuse of healthcare services, and forms the basis for HDAS's Unwarranted Variation Analy-tics. These proprietary analytics drive HDAS's range of analytic solutions, which include predictive modeling and provider performance measurement.
HDAS currently supports more than 19 million individual lives.
Endocare looking to trade on exchange
Endocare (Irvine, California), which is focused on the development of minimally invasive technologies for tissue and tumor ablation along with vacuum technologies for erectile dysfunction, said it is taking certain regulatory and legal steps designed to pave the way towards gaining a listing on a national stock market or exchange.
Endocare Chairman and CEO Craig Davenport said, “Having been in SEC filing compliance for well over a year, our board and management believe that it is in the company’s best interest to complete the necessary steps required to have our stock listed on a national market or exchange as it was until early 2003.”
He added: “Alternative markets such as the ‘Pink Sheets,’ where the company’s stock now trades, are considered to be less efficient and not as widely followed as other exchanges or markets like those operated by the Nasdaq Stock Market or the American Stock Exchange. Furthermore, many institutional investors are prohibited from investing in companies listed on the ‘Pink Sheets.’”